Jacobson Center for Clinical & Translational Research

Main Menu


Additional Information


Contact Us

Multiple Sclerosis Research

Study Title:  A 12 month, Randomized, rater- and dose-blinded study to compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 Administered Orally Once Daily in patients with Relapsing-Remitting Multiple Sclerosis (FTY720D2312)  (Identifier: NCT01633112)

Study Purpose:  The purpose of this study is to compare 2 doses (0.25 mg and 0.50 mg) of fingolimod to glatiramer acetate (20 mg) and to evaluate the efficacy of fingolimod 0.25 mg for the treatment of patients with relapsing-remitting MS (RRMS).

Principal Investigator: Boyd Koffman, MD

Study Coordinator:  Andrea Korsnack, RN.  For more information, please call at 419-383-3801.



Last Updated: 7/21/16